Skip to content
Arvinas logo
Search
Close
Arvinas logo
Search
Close

Publication Year: 2016

Targeted and Selective Degradation of ERa by PROTACs®

BRD4 Proteolysis Targeting Chimera (PROTAC®) ARV-825, Causes Sustained Degradation of BRD4 and Modulation of Chemokine Receptors, Cell Adhesion and Metabolic Targets in Leukemia Resulting in Profound Anti-Leukemic Effects

Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs®) Exert Potent Single Agent and Synergistic Activity with Ibrutinib and Venetoclax Against Human Mantle Cell Lymphoma Cells

Superior Lethal Activity of Novel BET Protein Proteolysis Targeting Chimera (BETP-PROTACs®) Versus Betp Bromodomain Inhibitor (BETi) Against Post-Myeloproliferative Neoplasm (MPN) Secondary(s) AML Cells

BET-PROTACs® Are More Broadly Effective Than BET Inhibitors

BRD4 Degradation by PROTACs® Represents a More Effective Therapeutic Strategy than BRD4 Inhibitors in Ovarian Cancer

Hijacking Ubiquitin E3 Ligases Using PROTAC® Technology to Effectively Degrade BRD4 and Achieve Anti-tumor Efficacy

PROTAC® BRD4 Degraders Allow a More Effective Therapeutic Strategy than BRD4 Inhibitors

Arvinas logo
  • Careers
  • Privacy Policy
  • Terms of Use
Menu
  • Careers
  • Privacy Policy
  • Terms of Use
Linkedin-in Twitter

© 2023 Arvinas. All rights reserved.

Arvinas logo
Search
Close
  • Our Science
    • PROTAC® Discovery Engine
    • Scientific Publications
    • Partnerships
  • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Research & Development
    • Pipeline
    • Androgen Receptor
    • Estrogen Receptor
    • Neuroscience
  • Careers & Culture
    • Open Positions
    • Life in New Haven
    • Our Values
    • Benefits
    • Giving Back
  • Patients
    • Patients with Breast Cancer
    • Patients with Prostate Cancer
    • Clinical Trials
    • Expanded Access Policy
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
Menu
  • Contact Us
Linkedin-in Twitter
Skip to content